Skip to Content
Søg Menu

Nye McDonald-kriterier for diagnosticering af MS

Nye McDonald-kriterier, publiceret i the Lancet, oktober 2025, forventes at føre til en hurtigere diagnosticering af MS, hurtigere igangsættelse af behandling og dermed forbedre behandlingen for personer med MS.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Sygdomsmodificerende behandling af attakvis og sekundær progressiv multipel sclerose

/ Jan Andreasen
MS

Towards Personalized MS Therapy: microRNAs as Early Indicators of Cladribine Response

/ Jan Andreasen
MS

Cladribine Shows a Robust Safety Profile – Both as First-Line and Subsequent Therapy in MS

/ Jan Andreasen
ECTRIMS25MS
Linda Forsberg

ECTRIMS 2025: Swedish Real-World MS Data Demonstrates Long-Term Safety and Effectiveness of Cladribine

/ Linda Forsberg
ECTRIMS25MS Play the Video 03:20
Nicolò Tedone

EAN 2025: Need for Tailored Assessment and Monitoring of Late-Onset MS

/ Nicolò Tedone
EAN25MS Play the Video 01:36
Mark S. Freedman

Treatment That Can Be Given in a Short Period of Time and Produce a Durable Response Would Lead to Better Safety for the Patients with MS

/ Mark S. Freedman
MS Play the Video 04:37
Patricia K. Coyle

MS Is Becoming a Milder Disease in the Near Future, Enabling a Normal Life

/ Patricia K. Coyle
MS Play the Video 05:54
Gavin Giovannoni

Paradigm Shift in the Treatment of Multiple Sclerosis

/ Gavin Giovannoni
MS Play the Video 04:56
Gavin Giovannoni

Cladribine in MS: A Key to Slowing Aging and Protecting Brain Health

/ Gavin Giovannoni
MS Play the Video 11:00

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top